Methods of treating chronic kidney disease (CKD) or ckd and hypertension with lorundrostat, or a combination of lorundrostat and a sglt2 inhibitor
EP4746887A1Pending Publication Date: 2026-05-27MINERALYS THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- MINERALYS THERAPEUTICS INC
- Filing Date
- 2024-07-17
- Publication Date
- 2026-05-27
AI Technical Summary
Technical Problem
Current treatments for chronic kidney disease (CKD) and hypertension are inadequate in effectively slowing disease progression and managing associated complications.
Method used
Administering lorundrostat, either alone or in combination with a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to patients with CKD and hypertension, with or without angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB).
Benefits of technology
Lorundrostat, when used alone or in combination with SGLT2 inhibitors, demonstrates efficacy in reducing albuminuria, slowing CKD progression, and managing hypertension, while potentially reducing adverse effects associated with other treatments.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2024038319_23012025_PF_FP_ABST
Abstract
This invention provides methods of treating chronic kidney disease (CKD) or CKD and hypertension in a subject afflicted with CKD or CKD and hypertension, the method comprising administering to the subject an amount of lorundrostat or a pharmaceutically acceptable salt thereof once per day, wherein the amount is effective to treat CKD or CKD and hypertension in the subject.
Need to check novelty before this filing date? Find Prior Art